Prevalent cases in the global Cystic Fibrosis market are expected to increase in the 0-35 year age group from 58,056 in 2012 to 68,373 in 2020. This would give an annual growth rate of 1.78% between 2012 and 2020.
National healthcare practices affect the diagnosis rate and survival rate of any disease, and CF patients can sometimes experience substantially different lives depending on the country they are born and treated in. CF patients in the US are more likely to live well into adulthood compared to several decades ago, and expect a median survival age of 37 years, showing a dramatic improvement of over the last 25 years.
The CF patient population's average survival age in the US has steadily increased due to early diagnosis and treatment with all 50 states screening for CF in newborns. As a result of this stringency, the National Cystic Fibrosis Patient Registry reported that 75.7% of patients with CF suffered no medical complications.
Similarly to the other markets, Spain's median age of death has increased in CF patients, with early screening and detection resulting in earlier treatment. The most common cause of CF-related death in Spain is respiratory failure, but improved treatment, lung transplants, and nutrition control is successfully tackling this problem.
In comparison, Germany boasts a relatively low crude mortality rate compared with most countries, but we believe that this may be due to CF deaths being underreported, undiagnosed, or undertreated.
For more information on the Global Cystic Fibrosis market, please click here: Global Cystic Fibrosis market
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.